These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 25774580)

  • 21. [About radio-opaque appearance of a phosphate binder, lanthanum carbonate].
    Montagnac R; Schillinger F
    Presse Med; 2010 Apr; 39(4):522-3. PubMed ID: 19423283
    [No Abstract]   [Full Text] [Related]  

  • 22. [Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control].
    Arenas MD; Malek T; Álvarez-Ude F; Gil MT; Moledous A; Reig-Ferrer A
    Nefrologia; 2010; 30(5):522-30. PubMed ID: 20613851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lanthanum carbonate as a first-line phosphate binder: the "cons".
    Drüeke TB
    Semin Dial; 2007; 20(4):329-32. PubMed ID: 17635823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Peritoneal dialysis-related infections].
    Lebeaux D; Touam M
    Rev Prat; 2014 May; 64(5):656-7. PubMed ID: 24923051
    [No Abstract]   [Full Text] [Related]  

  • 25. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.
    Fishbane S; Delmez J; Suki WN; Hariachar SK; Heaton J; Chasan-Taber S; Plone MA; Moe S
    Am J Kidney Dis; 2010 Feb; 55(2):307-15. PubMed ID: 20042256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy.
    Wilson R; Zhang P; Smyth M; Pratt R
    Curr Med Res Opin; 2009 Dec; 25(12):3021-8. PubMed ID: 19845495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
    Habbous S; Przech S; Martin J; Garg AX; Sarma S
    Value Health; 2018 Mar; 21(3):318-325. PubMed ID: 29566839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study.
    Al-Baaj F; Speake M; Hutchison AJ
    Nephrol Dial Transplant; 2005 Apr; 20(4):775-82. PubMed ID: 15703206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of continuous oral administration of lanthanum carbonate over 24 months.
    Ishizu T; Hong Z; Matsunaga T; Kaneko Y; Taru Y
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():22-8. PubMed ID: 23586509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate.
    Pennick M; Dennis K; Damment SJ
    J Clin Pharmacol; 2006 Jul; 46(7):738-46. PubMed ID: 16809799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.
    Kishi Y; Obara Y; Hara K; Yamashiro H; Kurosawa N; Takada D
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():9-13. PubMed ID: 24953760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continuous ambulatory peritoneal dialysis.
    O'Connor J; McLean G
    N Z Med J; 1983 Jan; 96(723):1-4. PubMed ID: 6571746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative evaluation of the in vitro efficacy of lanthanum carbonate chewable tablets.
    Yang Y; Bykadi S; Carlin AS; Shah RB; Yu LX; Khan MA
    J Pharm Sci; 2013 Apr; 102(4):1370-81. PubMed ID: 23334989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
    Finn WF; Joy MS;
    Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Additional reduction in serum phosphorus levels by pulverized lanthanum carbonate chewable in hemodialysis patients.
    Yamashita T; Ogawa T; Takahashi M; Mitsuhashi T; Shizuku J; Takahashi N; Ohba T; Miyajima S; Kabaya T; Otsuka K; Nitta K
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():54-9. PubMed ID: 23586514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Timing for Removal of Peritoneal Dialysis Catheters in Pediatric Renal Transplant Patients.
    Melek E; Baskın E; Gülleroğlu KS; Kırnap M; Moray G; Haberal M
    Exp Clin Transplant; 2016 Nov; 14(Suppl 3):74-77. PubMed ID: 27805518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate.
    Hutchison AJ; Speake M; Al-Baaj F
    Nephrol Dial Transplant; 2004 Jul; 19(7):1902-6. PubMed ID: 15199195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Why does a patient on hemodialysis have radiopaque material in his abdomen?].
    Aucella F; Marinelli T; Paoletti D; Vigilante M; Vocino V
    G Ital Nefrol; 2009; 26(2):246-9. PubMed ID: 19382081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Introduction to lanthanum carbonate: pharmacology, safety and tolerability].
    Rodríguez Portillo M
    Nefrologia; 2008; 28 Suppl 5():7-10. PubMed ID: 18847413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New acute peritoneal dialysis technique: wire-guide insertion and long-term indwelling of peritoneal catheter.
    Nakanishi T; Yanase M; Fujii M; Tanaka Y; Orita Y; Abe H
    Nephron; 1984; 37(2):128-32. PubMed ID: 6728087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.